CN102123697B - 用于口服给予蛋白质的方法和组合物 - Google Patents

用于口服给予蛋白质的方法和组合物 Download PDF

Info

Publication number
CN102123697B
CN102123697B CN200980132155.8A CN200980132155A CN102123697B CN 102123697 B CN102123697 B CN 102123697B CN 200980132155 A CN200980132155 A CN 200980132155A CN 102123697 B CN102123697 B CN 102123697B
Authority
CN
China
Prior art keywords
another embodiment
insulin
amount
protein
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980132155.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102123697A (zh
Inventor
米丽娅姆·基德隆
埃胡德·阿比特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ante Labei'ou Co Ltd
Original Assignee
Oramed Ltd
Entera Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oramed Ltd, Entera Bio Ltd filed Critical Oramed Ltd
Priority to CN201510226529.XA priority Critical patent/CN104857505A/zh
Publication of CN102123697A publication Critical patent/CN102123697A/zh
Application granted granted Critical
Publication of CN102123697B publication Critical patent/CN102123697B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN200980132155.8A 2008-08-18 2009-08-11 用于口服给予蛋白质的方法和组合物 Active CN102123697B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510226529.XA CN104857505A (zh) 2008-08-18 2009-08-11 用于口服给予蛋白质的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8981208P 2008-08-18 2008-08-18
US61/089,812 2008-08-18
PCT/IL2009/000786 WO2010020978A1 (en) 2008-08-18 2009-08-11 Methods and compositions for oral administration of proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510226529.XA Division CN104857505A (zh) 2008-08-18 2009-08-11 用于口服给予蛋白质的方法和组合物

Publications (2)

Publication Number Publication Date
CN102123697A CN102123697A (zh) 2011-07-13
CN102123697B true CN102123697B (zh) 2015-06-10

Family

ID=41706898

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980132155.8A Active CN102123697B (zh) 2008-08-18 2009-08-11 用于口服给予蛋白质的方法和组合物

Country Status (11)

Country Link
US (6) US9186412B2 (enExample)
EP (2) EP3741359A1 (enExample)
JP (3) JP5740689B2 (enExample)
CN (1) CN102123697B (enExample)
AU (1) AU2009283821B2 (enExample)
CA (1) CA2734442C (enExample)
ES (1) ES2823233T3 (enExample)
HK (1) HK1214153A1 (enExample)
NZ (1) NZ591497A (enExample)
RU (2) RU2494755C2 (enExample)
WO (1) WO2010020978A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108653234A (zh) * 2017-04-01 2018-10-16 中国科学院上海药物研究所 载有多肽蛋白类药物的固体颗粒物及包含该颗粒物的双肠溶固体制剂、其制备方法及用途

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621577C (en) * 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
JP5395160B2 (ja) 2008-03-26 2014-01-22 オラムド エルティーディー． タンパク質の経口投与方法及び組成物
JP2011519915A (ja) 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
CN110437321A (zh) 2010-07-09 2019-11-12 阿菲博迪公司 多肽
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
HUE066433T2 (hu) 2012-02-01 2024-08-28 Oramed Ltd Proteáz inhibitort tartalmazó készítmények, azokat tartalmazó összetevõk, valamint eljárások azok elõállítására és felhasználására
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
KR102266299B1 (ko) * 2012-03-22 2021-06-18 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
ES2871328T3 (es) * 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
JP6590695B2 (ja) 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
EP4215205A1 (en) 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CN104707131A (zh) * 2013-12-13 2015-06-17 上海建华精细生物制品有限公司 一种药物组合物及其制备方法和用途
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN107205949A (zh) * 2015-01-29 2017-09-26 诺和诺德股份有限公司 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
CN114949185A (zh) * 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
NZ735250A (en) 2015-07-08 2020-08-28 Research & Business Found Sungkyunkwan Univ Pyrrolidine carboxamido derivatives and methods for preparing and using the same
US20170189363A1 (en) * 2015-12-30 2017-07-06 Noven Pharmaceuticals, Inc. Gastric acid modulators for oral delivery of peptides and proteins
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
NZ751668A (en) 2016-08-17 2022-07-29 Entera Bio Ltd Formulations for oral administration of active agents
EA201892396A1 (ru) * 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20180271792A1 (en) * 2017-03-23 2018-09-27 Rezolute, Inc. Oral delivery of physiologically active substances
CN108653233A (zh) * 2017-04-01 2018-10-16 苏州苏融生物医药有限公司 一种具有生物粘附性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途
CN108653719A (zh) * 2017-04-01 2018-10-16 苏州苏融生物医药有限公司 一种具有粘液穿透性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途
WO2019042247A1 (zh) * 2017-08-28 2019-03-07 江苏恒瑞医药股份有限公司 一种cyp17抑制剂的药物组合物及其制备方法
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN109260464B (zh) * 2018-10-29 2021-10-15 兆科药业（合肥）有限公司 抗血小板溶栓素的新用途
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
TWI821541B (zh) * 2019-03-08 2023-11-11 奧孟亞股份有限公司 Pth類似物之口服製劑及治療
JP7767264B2 (ja) 2019-09-02 2025-11-11 ノヴォ ノルディスク アー／エス Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
CA3152944A1 (en) * 2019-09-03 2021-03-11 Amgen Inc. Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
CN114641276A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP4122483B1 (en) * 2020-03-18 2025-04-30 Xizang Haisco Pharmaceutical Co., Ltd. Oral pharmaceutical composition
JP7777085B2 (ja) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
CN111909955B (zh) * 2020-08-10 2021-12-31 安徽新熙盟生物科技有限公司 重组MANNase-GLP-1及同源物的制备及应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
MX2024000768A (es) 2021-07-15 2024-02-12 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil) amino)caprilico.
MX2024002306A (es) 2021-08-23 2024-03-07 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A Nanosistemas cristalinos liquidos liotropicos con macromoleculas bioactivas encapsuladas.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5426616A (en) 1977-07-30 1979-02-28 Fujitsu Ltd Input level monitor system for level adjuster and automatic restoration system for level adjuster
JPS5740689A (en) 1980-08-25 1982-03-06 Tokyo Shibaura Electric Co Nuclear reactor shutdown device
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS60224638A (ja) 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
CZ299295B6 (cs) * 1995-03-31 2008-06-11 Emisphere Technologies, Inc. Sloucenina pro dodávání aktivních cinidel a zpusob její prípravy, farmaceutická kompozice s jejím obsahem a forma dávkové jednotky s obsahem této kompozice
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
HU229613B1 (en) 2001-06-01 2014-03-28 Novartis Ag Oral administration of parathyroid hormone and calcitonin
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
ES2465496T3 (es) 2003-01-06 2014-06-05 Emisphere Technologies, Inc. Terapia de insulina oral nocturna
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物
PL1651249T3 (pl) * 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
JP2005281231A (ja) * 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
EP1750729A2 (en) 2004-05-06 2007-02-14 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
JP2006111558A (ja) * 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
WO2006103657A2 (en) 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
CA2621577C (en) * 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US8703821B2 (en) * 2006-04-18 2014-04-22 Emisphere Technologies Inc. Dialkyl ether delivery agents
RU2494755C2 (ru) * 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108653234A (zh) * 2017-04-01 2018-10-16 中国科学院上海药物研究所 载有多肽蛋白类药物的固体颗粒物及包含该颗粒物的双肠溶固体制剂、其制备方法及用途
CN108653234B (zh) * 2017-04-01 2021-02-26 中国科学院上海药物研究所 载有多肽蛋白类药物的固体颗粒物及包含该颗粒物的双肠溶固体制剂、其制备方法及用途

Also Published As

Publication number Publication date
JP2012500254A (ja) 2012-01-05
AU2009283821B2 (en) 2014-05-29
CN102123697A (zh) 2011-07-13
ES2823233T3 (es) 2021-05-06
US20250281396A1 (en) 2025-09-11
JP2016185970A (ja) 2016-10-27
US12311051B2 (en) 2025-05-27
AU2009283821A1 (en) 2010-02-25
US20160058699A1 (en) 2016-03-03
EP2331072A4 (en) 2013-12-18
RU2013130611A (ru) 2015-01-10
NZ591497A (en) 2012-11-30
US10010503B2 (en) 2018-07-03
CA2734442C (en) 2016-08-16
US20190380953A1 (en) 2019-12-19
US20180280292A1 (en) 2018-10-04
US9186412B2 (en) 2015-11-17
RU2011108334A (ru) 2012-09-27
CA2734442A1 (en) 2010-02-25
EP2331072B8 (en) 2020-08-26
EP3741359A1 (en) 2020-11-25
JP6124095B2 (ja) 2017-05-10
JP5740689B2 (ja) 2015-06-24
US20220151919A1 (en) 2022-05-19
US20110142800A1 (en) 2011-06-16
JP2015107990A (ja) 2015-06-11
HK1214153A1 (zh) 2016-09-02
EP2331072A1 (en) 2011-06-15
WO2010020978A1 (en) 2010-02-25
EP2331072B1 (en) 2020-07-22
US11246827B2 (en) 2022-02-15
RU2646828C2 (ru) 2018-03-07
JP5981575B2 (ja) 2016-08-31
US10420721B2 (en) 2019-09-24
RU2494755C2 (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
US12311051B2 (en) Methods and compositions for oral administration
US10881714B2 (en) Methods and compositions for oral administration of proteins
CN101547702B (zh) 用于口服给药蛋白质的方法和组合物
CN104857505A (zh) 用于口服给予蛋白质的方法和组合物
AU2015243030B2 (en) Methods and compositions for oral administration of proteins
AU2014218446B2 (en) Methods and compositions for oral administration of proteins
HK40039520A (en) Methods and compositions for oral administration of proteins
AU2013237663B2 (en) Methods and compositions for oral administration of proteins
HK1158938A (en) Methods and compositions for oral administration of proteins
HK1158938B (en) Methods and compositions for oral administration of proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ANTE LABEI OU CO., LTD.

Free format text: FORMER OWNER: ORAMED INC.

Effective date: 20111209

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20111209

Address after: Israel Jerusalem

Applicant after: Ante Labei'ou Co., Ltd.

Address before: Israel Jerusalem

Applicant before: Oramed Pharmaceuticals Inc.

C14 Grant of patent or utility model
GR01 Patent grant